ReviewTaiwan journal of ophthalmology
Molecular diagnosis of vitreoretinal lymphoma.
Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitreoretinal lymphoma (VRL) is a rare ocular malignancy that involves the retina, the retinal pigment epithelium, and the vitreous. It is a subtype of primary central nervous system lymphoma (CNSL). Most cases of VRL and CNSL are classified as diffuse large B-cell lymphoma. Despite its indolent nature, VRL can lead to permanent vision loss and even death due to CNS involvement. The gold standard for diagnosing VRL is the identification of lymphoma cells in a vitreous biopsy. However, diagnosis is challenging due to the rarity and fragility of lymphoma cells. Consequently, various diagnostic methods, such as interleukin level measurement, immunoglobulin clonality assays, flow cytometry, and molecular analysis have been developed to improve diagnostic accuracy. Tools from molecular biology, such as next-generation sequencing and single-cell based analyses, are being investigated as emerging diagnostic modalities. This review aims to discuss the conventional and up-to-date molecular tools for VRL diagnosis and to present important genetic variations and their clinical implications in VRL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.